智通财经APP获悉,生物技术公司Monte Rosa Therapeutics(GLUE.US)与诺华制药(NVS.US)签署了一项独家许可协议,以推进其用于自身免疫性疾病的VAV1导向的分子胶降解剂(MGD),包括MRT-6160。受此消息提振,Monte Rosa股价周一美股盘前一度大涨近50%。
Monte Rosa将继续负责完成正在进行的MRT-6160的1期临床研究,并有资格在2期研究启动后获得高达21亿美元的开发、监管和销售里程碑,以及美国以外净销售额的分层版税。
Monte Rosa将共同资助MRT-6160在美国的任何3期临床开发,并分享与生产和商业化相关的任何损益。
诺华制药将负责所有临床开发和商业化,从2期临床研究开始。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.